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LWhy change?John W. Hammon, MDThis provocative editorial seeks to convince the reader-
ship that hyperkalemic depolarizing cardiac arrest afforded
by potassium-containing cardioplegic solutions can be dele-
terious to cardiac function and may be responsible for some
of the untoward effects of ischemic arrest often used for car-
diac surgical operations today. Dr Dobson provides evi-
dence that depolarizing cardiac arrest can have several
deleterious effects, including alterations in the sodium/cal-
cium homeostasis, vasoconstriction, and direct cellular in-
jury provoking an inflammatory response. He further
suggests that a compound composed of 2 molecules, specif-
ically adenosine and lidocaine, can achieve the same electro-
mechanical arrest at higher concentration than that used for
reducing inflammation and other effects while avoiding
some of the deleterious effects of hyperkalemia.
The potential problems associated with potassium cardio-
plegia have been discussed for some time, and 2 particularly
good articles are referenced by Dr Dobson (references 5
and 17).
Perhaps themost important feature of the cardioplegia con-
troversy is that there is no great impetus for change in this
country or the world today because the results of cardiac
surgery have improved to the point where it would take
a profound improvement to alter morbidity and mortality
outcomes.Many surgeons, including our group, use an arrest-
ing concentration of potassium (25 mEq/L) in a buffered
blood solution and switch to a lower concentration of potas-
sium (10 mEq/L) for subsequent doses delivered intermit-
tently antegrade and retrograde. High volumes of potassium
derived from cardioplegia can cause systemic hyperkalemia,
which can be deleterious in patients with renal insufficiency.
Likewise, the emergence of cardiac electrical activity associ-
ated with too little cardioplegia can cause ischemic myocar-
diac damage.
In the real world of cardiac surgery, many operations
with ischemic arrest periods of more than 90 minutes can
be carried out in patients with normal ventricles with little,
if any, evidence of cardiac damage postoperatively. There-
fore, why the interest in a new compound? Almost all car-From the Department of Cardiothoracic Surgery, Wake Forest University School of
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patients with poor left ventricular function that required ex-
tensive cardiac surgery in which significant myocardial dys-
function occurred postoperatively. This is particularly true
if some of the preoperative myocardial injury is acute. In
these cases, high doses of inotropic drugs, aortic balloon
pump assist, or left ventricular assist device implantation
may be necessary to preserve life. This does not happen of-
ten, but when it does it often ends with a disappointing re-
sult. Is this because of the toxic effects of cardioplegia,
ischemic arrest, or both? The answer is not exactly known,
but any surgeon who has been in that situation would wish
for better myocardial protection.
A recent study of perioperative ischemia demonstrated
low but significant elevations in cardiac isoenzymes associ-
ated with ischemic arrest and hyperkalemic cardioplegia.1
This would make one suspicious that a low level of myocar-
dial damage is produced during hyperkalemic cardioplegic
protection from ischemic arrest that may not become mani-
fest unless significant myocardial dysfunction was present
preoperatively.
So what needs to be done in 2010? There are many an-
ecdotal statements from surgeons who have used the com-
bination of adenosine and lidocaine now marketed under
the trademark of Adenocaine (Hibernation Therapeutics,
Wicklow, Ireland). Because there has been no significant
clinical research for this compound, I would vote for 2 dis-
tinct phases of investigation. In the first, this drug could be
used in crystalloid cardioplegia or with blood (4:1 blood:-
crystalloid or microplegia formulations) and varying com-
binations of potassium and other additives to investigate
the animal model of acute myocardial ischemia and
reperfusion, as suggested and used by Dr Jakob Vinten-
Johansen to develop better myocardial protection tech-
niques for the sickest hearts.2
In addition, one of the significant needs in our profession
is for the ability to preserve the heart destined for trans-
plantation. Significant preliminary evidence is presented
in this editorial for a role of Adenocaine in improved pres-
ervation of the donor heart. I would therefore suggest that
an experimental protocol be used to test this non-
depolarizing arrest on a transplantation animal model. If
these animal studies are promising, then we could rapidly
move into a clinical testing phase in both the arenas of
damaged hearts for repair and preservation of the heart
for transplantation.
We should be grateful that Dr Dobson and associates have
persisted in their work and laid the groundwork for perhapsgery c December 2010
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patients with severe heart disease.
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